Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Dost Sarpel, Esha Baichoo & Douglas T. Dieterich. (2016) Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening. Expert Review of Anti-infective Therapy 14:5, pages 511-521.
Read now
Read now
Articles from other publishers (14)
Paul G. Carty, Conor Teljeur, Cillian F. De Gascun, Paddy Gillespie, Patricia Harrington, Aiden McCormick, Michelle O’Neill, Susan M. Smith & Mairin Ryan. (2022) Another Step Toward Hepatitis C Elimination: An Economic Evaluation of an Irish National Birth Cohort Testing Program. Value in Health 25:12, pages 1947-1957.
Crossref
Crossref
Dong Hyun Sinn, Danbee Kang, Yun Soo Hong, Kwang Cheol Koh, Eliseo Guallar, Juhee Cho & Geum-Youn Gwak. (2021) Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study. PLOS ONE 16:8, pages e0255624.
Crossref
Crossref
El‐Sayed Ibrahim, Mohamed Abdel‐Samiee, Mohamed I. Youssef, Helmy El‐Shazly, Abd‐ElAleem A.El‐Gendy, Ayman Ahmed Sakr, Doaa Elwazzan, Mervat Ragab Nassar, Amr Elshormilisy, Ahmad Madkour, Mostafa Kamal, Yasmine M. Amrousy, Sally Waheed Elkhadry & Eman Abdelsameea. (2020) Variceal recurrence 4 years post endoscopic band ligation in hepatitis C patients who achieved sustained virological response with oral direct‐acting antiviral therapy. Journal of Viral Hepatitis 28:2, pages 279-287.
Crossref
Crossref
Nicole J. Kim, Cameron J. Locke, Helen Park, Catherine Magee, Peter Bacchetti & Mandana Khalili. (2018) Race and Hepatitis C Care Continuum in an Underserved Birth Cohort. Journal of General Internal Medicine 34:10, pages 2005-2013.
Crossref
Crossref
Christian B. Ramers, Jie Liu & Catherine Frenette. (2019) Barriers to Treatment of Hepatitis C Virus in the Direct-Acting Antiviral Era. Current Treatment Options in Infectious Diseases 11:2, pages 92-102.
Crossref
Crossref
M. C. Politi, N. George, T. Li, K. M. Korenblat, K. J. Fowler, C. Ho, A. Liapakis, D. Roth & J. Yee. (2018) Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease. Pilot and Feasibility Studies 4:1.
Crossref
Crossref
Geoffrey Dusheiko. 2018. Sherlock's Diseases of the Liver and Biliary System. Sherlock's Diseases of the Liver and Biliary System
436
467
.
Claudia C Dobler, Rebecca L Morgan, Yngve Falck-Ytter, Victor M Montori & M Hassan Murad. (2018) Assessing the validity of surrogate endpoints in the context of a controversy about the measurement of effectiveness of hepatitis C virus treatment. BMJ Evidence-Based Medicine 23:2, pages 50-53.
Crossref
Crossref
Benedikte Bjøro, Olav Dalgard, Håvard Midgard, Hans Verbaan, Milada Cvancarova Småstuen & Tone Rustøen. (2018) Increased hope following successful treatment for hepatitis C infection. Journal of Advanced Nursing 74:3, pages 724-733.
Crossref
Crossref
Antonio Massimo Ippolito, Angelo Iacobellis, Michele Milella, Fabio Conti, Vincenzo Messina, Maria Rosa Valvano, Grazia Anna Niro, Filomena Morisco, Michele Barone, Antonio Patrizio Termite, Giuseppina Brancaccio & Angelo Andriulli. (2017) Hepatitis C Virus Clearance in Older Adults. Journal of the American Geriatrics Society 66:1, pages 85-91.
Crossref
Crossref
M.J. Vivancos, A. Moreno & C. Quereda. (2018) Treatment of hepatitis C virus with direct-acting antivirals: Practical aspects and current situation. Revista Clínica Española (English Edition) 218:1, pages 29-37.
Crossref
Crossref
M.J. Vivancos, A. Moreno & C. Quereda. (2018) Tratamiento del virus de la hepatitis C con antivirales de acción directa: Aspectos prácticos y situación actual. Revista Clínica Española 218:1, pages 29-37.
Crossref
Crossref
Geoffrey Dusheiko. (2017) The impact of antiviral therapy for hepatitis C on the quality of life: a perspective. Liver International 37, pages 7-12.
Crossref
Crossref
Hugo Ramón Rosen. (2016) “Hep C, where art thou”: What are the remaining (fundable) questions in hepatitis C virus research?. Hepatology 65:1, pages 341-349.
Crossref
Crossref